Vermillion has received a notice of allowance from the United States Patent and Trademark Office for a patent entitled, Biomarkers for Ovarian Cancer.
The patent makes claims in the uses of a urinary Small MBL-associated protein C-terminal fragment (sMAP) in the diagnosis of ovarian cancer, ovarian cancer monitoring, and patient management.
OVA1 is a blood test for pre-surgical assessment of ovarian tumors for malignancy, using a multi-biomarker approach.
Vermillion chief science officer and R&D VP Donald Munroe said: "We believe these tools represent the best diagnostic tools available today in the diagnosis and management of ovarian cancer, which is the leading cause of gynecologic cancer mortality."
Source:
http://regulatoryaffairs.pharmaceutical-business-review.com/news/vermillion-receives-notice-of-allowance-for-biomarker-patent-in-us-170412
